Read by QxMD icon Read


Paul Eichinger, Simon Schön, Viola Pongratz, Hanni Wiestler, Haike Zhang, Matthias Bussas, Muna-Miriam Hoshi, Jan Kirschke, Achim Berthele, Claus Zimmer, Bernhard Hemmer, Mark Mühlau, Benedikt Wiestler
Background Administration of a gadolinium-based contrast material is widely considered obligatory for follow-up imaging of patients with multiple sclerosis (MS). However, advances in MRI have substantially improved the sensitivity for detecting new or enlarged lesions in MS. Purpose To investigate whether the use of contrast material has an effect on the detection of new or enlarged MS lesions and, consequently, the assessment of interval progression. Materials and Methods In this retrospective study based on a local prospective observational cohort, 507 follow-up MR images obtained in 359 patients with MS (mean age, 38...
March 12, 2019: Radiology
Seema Rohilla, Harender K Garg, Ishwar Singh, Rohtas K Yadav, Dhara B Dhaulakhandi
Introduction: This study was conducted to grade meningiomas based on relative Cerebral Blood Volume (rCBV) and Apparent Diffusion Coefficient (ADC) to help surgeons plan the approach and extent of operation as well as decide on the need of any adjuvant radio/chemo therapy. The current and evolving genomic, proteomic, and spectroscopic technologies are also discussed which can supplement the current radiologic methods and procedures in grading meningiomas. Methods: A total of 35 patients with meningioma prospectively underwent basic MR sequences (T1W, T2W, T2W/FLAIR) in axial, sagittal and coronal planes followed by Diffusion Weighted (DW) imaging having b value of 1000 (minimum ADC values used for analysis)...
November 2018: Basic and Clinical Neuroscience
Aida Kiviniemi, Maria Gardberg, Paul Ek, Janek Frantzén, Johan Bobacka, Heikki Minn
PURPOSE: To quantitate gadolinium deposits in gliomas and adjacent normal brain specimens, and to evaluate their association with tumor contrast enhancement and the type of gadolinium-based contrast agent (GBCA) used. METHODS: A total of 69 patients with primary glioma who underwent contrast-enhanced magnetic resonance imaging (MRI) prior to surgery were included in this retrospective study. Gadolinium was measured from histologically viable tumor, normal brain, and necrosis within the sample, when available, using inductively coupled plasma mass spectrometry (ICP-MS)...
February 2, 2019: Neuroradiology
Philipp Eisele, Kristina Szabo, Anne Ebert, Alexander Radbruch, Michael Platten, Stefan O Schoenberg, Achim Gass
OBJECTIVE: Over the last years several studies reported an increased signal intensity (SI) of the dentate nucleus (DN) on unenhanced T1-weighted images after repeated application of gadolinium-based contrast agents (GBCAs), suggesting gadolinium deposition. The aim of this study was to investigate with diffusion-weighted MRI possible tissue abnormalities of the DN in multiple sclerosis (MS) patients. MATERIAL AND METHODS: We retrospectively identified seventeen patients with at least six contrast-enhanced MRI examinations by using the linear GBCA gadopentate dimeglumine and twenty-three patients with the exclusive use of the macrocyclic contrast agent gadoterate meglumine followed by another 3 Tesla MRI scan including unenhanced T1-weighted and diffusion-weighted images...
January 7, 2019: Magnetic Resonance Imaging
Amir Ali Rahsepar, Ahmadreza Ghasemiesfe, Kenichiro Suwa, Ryan S Dolan, Monda L Shehata, Monica J Korell, Nivedita K Naresh, Michael Markl, Jeremy D Collins, James C Carr
PURPOSE: Late gadolinium enhancement cardiac MR (LGE-CMR) and extracellular volume fraction (ECV-CMR) are widely used to evaluate macroscopic and microscopic myocardial fibrosis. Macrocyclic contrast media are increasingly used off-label for myocardial scar assessment, given the superior safety profile of these agents. We aimed to assess the performance of two macrocyclic contrast agents, gadoterate meglumine and gadobutrol, for the evaluation of myocardial scar. MATERIAL AND METHODS: Forty subjects (61 ± 11 years, 67...
January 7, 2019: European Radiology
Paola Clauser, Thomas H Helbich, Panagiotis Kapetas, Katja Pinker, Maria Bernathova, Ramona Woitek, Andreas Kaneider, Pascal A T Baltzer
BACKGROUND: Contrast-enhanced magnetic resonance imaging (CE-MRI) of the breast is highly sensitive for breast cancer detection. Multichannel coils and 3T scanners can increase signal, spatial, and temporal resolution. In addition, the T1 -reduction effect of a gadolinium-based contrast agent (GBCA) is higher at 3T. Thus, it might be possible to reduce the dose of GBCA at 3T without losing diagnostic information. PURPOSE: To compare a three-quarter (0.075 mmol/kg) dose of the high-relaxivity GBCA gadobenate dimeglumine, with a 1...
December 15, 2018: Journal of Magnetic Resonance Imaging: JMRI
Salem Hannoun, Rayane Issa, Nabil K El Ayoubi, Ribal Haddad, Marwa Baalbaki, Bassem I Yamout, Samia J Khoury, Roula Hourani
RATIONALE AND OBJECTIVES: Previous studies on possible accumulation of gadolinium-based contrast agents (GBCA) in the brain suggest that macrocyclic GBCA are less likely to accumulate than linear GBCA. However, conflicting results have been reported, especially in MS. The aim of this study is to investigate retrospectively the correlation between gadoterate-meglumine (macrocyclic GBCA) use and T1 signal intensity changes (SI) in the dentate nucleus and the GP on unenhanced T1-weighted images in a large cohort of MS patients...
December 5, 2018: Academic Radiology
Maria Elena Laino, Serena Monti, David S Klimstra, Laura H Tang, Lorenzo Mannelli
A 7-year-old patient with a stage 4 neuroblastoma underwent chemotherapy, surgery, myeloablative therapy, external beam radiotherapy, and Isoretinoin treatment. A posttreatment magnetic resonance examination performed administering gadoteric acid as contrast agent showed 2 new hypervascular hepatic lesions, suspicious for metastases. A second magnetic resonance imaging performed using a liver-specific contrast medium (gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid) demonstrated that these lesions were consistent with treatment-related focal nodular hyperplasia...
November 28, 2018: Journal of Pediatric Hematology/oncology
Björn Friebe, Frank Godenschweger, Mahsa Fatahi, Oliver Speck, Dirk Roggenbuck, Dirk Reinhold, Annika Reddig
BACKGROUND: To investigate a potentially amplifying genotoxic or cytotoxic effect of different gadolinium-based contrast agents (GBCAs) in combination with ultra-high-field 7-T magnetic resonance imaging (MRI) exposure in separated human peripheral blood lymphocytes. METHODS: This in vitro study was approved by the local ethics committee and written informed consent was obtained from all participants. Isolated lymphocytes from twelve healthy donors were incubated with gadobutrol, gadoterate meglumine, gadodiamide, gadopentetate dimeglumine, or gadoxetate either alone or combined with 7-T MRI (1 h)...
November 28, 2018: European Radiology Experimental
Sabrina Kröger, Michael Sperling, Uwe Karst
A quantitative dried blood spot (DBS) method based on direct sampling by means of laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) is presented. Gadolinium-based contrast agents were used as model metallodrugs with a significant relevance for pharmaceutical applications. Challenges regarding the ablation of the complex blood-filter matrix were characterized and successfully addressed by a thorough adaption of the laser ablation conditions. Especially the laser fluence was optimized with respect to the particle size distribution of the generated aerosol as monitored by an optical particle counter...
January 2019: Journal of Trace Elements in Medicine and Biology
Won Jang, Hyo Sung Kwak, Gyung Ho Chung, Seung Bae Hwang
The original version of this article, published on 19 March 2018, unfortunately contained a mistake. In the section "MR examination," the contrast medium Gadoterate meglumine was incorrectly named Gadodiamide.
November 19, 2018: European Radiology
Laura K Young, Shona Z Matthew, J Graeme Houston
OBJECTIVES: Recent safety concerns regarding gadolinium-based contrast agents (GdCAs) concluded with the suspension of some agents from the European market, yet a clinical consequence remains unknown. We used electronic health records to investigate the incidence of potential toxicity to gadoteric acid (Dotarem®) within our local population, including those with renal insufficiency (RI). METHODS: Data for patients who underwent contrast-enhanced MRI were identified, stratified by renal function at time of scan and retrospectively followed using routinely collected health data...
October 1, 2018: European Radiology
Fatma Beyazal Celiker, Levent Tumkaya, Tolga Mercantepe, Mehmet Beyazal, Arzu Turan, Hatice Beyazal Polat, Zehra Topal Suzan, Mehmet Fatih Inecikli, Kerimali Akyildiz, Adnan Yilmaz
BACKGROUND: Gadolinium-based contrast agents are complex chelates to provide contrast in NRI. However, recent studies have highlighted the deposition of free Gd+3 ion in various tissues. PURPOSE: To evaluate the histopathological and immunohistochemical changes on rat kidney tissue following both macrocyclic (gadoteric acid) and linear (gadodiamide) agents under the hypothesis that gadolinium-based contrast agents (GBCA) lead to toxic, free Gd+3 accumulation in tissues...
September 13, 2018: Journal of Magnetic Resonance Imaging: JMRI
Giovanna Stefania Colafati, Enrica Rossi, Chiara Carducci, Simone Piga, Ioan Paul Voicu, Angela Mastronuzzi, Paolo Tomà
BACKGROUND: Given the recent concerns about gadolinium-based contrast agent safety, dose reduction strategies are being investigated. OBJECTIVE: To compare half-dose and standard full-dose gadoterate meglumine at 3-tesla (T) MRI in paediatric bone and soft-tissue diseases. MATERIALS AND METHODS: We prospectively enrolled 45 children (age range 2.7 months to 17.5 years, median age 8.7 years, 49 total anatomical segments) with bone and soft-tissue diseases (neoplastic, inflammatory/infectious, ischaemic and vascular) imaged at 3-T MRI...
November 2018: Pediatric Radiology
Seokha Jin, MungSoo Kang, HyungJoon Cho
In this study, we quantified perfusion deficits using dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) with an extravasating contrast agent (CA). We also investigated the efficacy of leakage compensation from CA pre-load in brains from post-ischemic rat models without significant dynamic contrast-enhanced MRI (DCE-MRI)-derived vessel wall permeability. DSC measurements were obtained using fast (0.3 s) echo-planar imaging in both normal rats and rats with transient middle carotid artery occlusion (MCAO) (1-h MCAO, 24-h reperfusion) after successive administrations of gadoterate meglumine (Dotarem) and intravascular superparamagnetic iron oxide nanoparticles (SPION)...
2018: PloS One
Yuya Makino, Satoru Akimoto, Hirobumi Hoshino
The purpose of this study was to evaluate the enhancement profile of 1.0M gadobutrol (high concentration: HC) in comparison to 0.5M gadopentetate dimeglumine and gadoterate meglumine (low concentration: LC) in dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) of prostate. In total, 48 patients who were diagnosed with prostate cancer by radiologist were included. Each patient was examined after intravenous injection of 0.1 mmol/kg body weight contrast agent with flow rate of 1.5 (HC) or 3.0 mL/s (LC)...
2018: Nihon Hoshasen Gijutsu Gakkai Zasshi
Takeshi Hara, Takeshi Ogata, Hiroko Wada, Takayuki Yabuki, Susumu Kanazawa
Introduction: Gadobutrol (Gd-DO3A-butrol) (Gadovist®) is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI) formulated at 1.0 mmol Gd/ml. Gadobutrol's higher concentration compared to other contrast agents (0.5 mmol Gd/ml) is associated with higher T1 relaxivity. We examined whether gadobutrol increases the accuracy of prostate cancer detection using dynamic contrast-enhanced MRI. Materials and Methods: Multiparametric MRI was performed in 379 patients: 94 patients received 1 M gadobutrol while 285 randomly received equivalent doses of 0...
June 2018: Current Urology
Marlène Rasschaert, Josef A Schroeder, Ting-Di Wu, Sergio Marco, Andréa Emerit, Heiko Siegmund, Claudia Fischer, Nathalie Fretellier, Jean-Marc Idée, Claire Corot, Christoph Brochhausen, Jean-Luc Guerquin-Kern
PURPOSE: The aim of this study was to investigate, based on in-depth multimodal imaging, the presence of Gd deposits, their ultrastructure, location, and co-location with endogenous elements, in the cerebellum, after repeated administrations of gadolinium-based contrast agents (GBCAs). METHODS: Rats sensitized by subtotal nephrectomy received 20 daily intravenous injections of 0.6 mmol Gd/kg for 5 weeks of commercial forms of either gadoterate, gadobenate or gadodiamide, or saline (n = 2/group)...
September 2018: Investigative Radiology
Philippe Robert, Stefanie Fingerhut, Cécile Factor, Véronique Vives, Justine Letien, Michael Sperling, Marlène Rasschaert, Robin Santus, Sébastien Ballet, Jean-Marc Idée, Claire Corot, Uwe Karst
Purpose To compare the long-term brain elimination kinetics and gadolinium species in healthy rats after repeated injections of the contrast agents gadodiamide (a linear contrast agent) or gadoterate (a macrocyclic contrast agent). Materials and Methods Nine-week-old rats received five doses of 2.4 mmol gadolinium per kilogram of body weight over 5 weeks and were followed for 12 months with T1-weighted MRI (n = 140 rats, corresponding to seven time points, two contrast agents, and 10 rats per group). Animals were sacrificed at 1 week, 1 month, and 2, 3, 4, 5, and 12 months after the last injection...
August 2018: Radiology
Florian Berger, Rahel A Kubik-Huch, Tilo Niemann, Hans Ruedi Schmid, Michael Poetzsch, Johannes M Froehlich, Jürg H Beer, Michael J Thali, Thomas Kraemer
Purpose To evaluate whether gadolinium penetrates human cerebrospinal fluid (CSF) after MR imaging (MRI) with a gadolinium-based contrast agent (GBCA). Materials and Methods For this retrospective study, the authors analyzed 60 CSF samples from 57 patients (median age, 50 years; range, 3-92 years) who underwent one contrast material-enhanced MRI examination with gadoterate meglumine within 60 days of CSF extraction between January and December 2016. CSF samples from patients who underwent MRI without contrast material administration (n = 22) or those who underwent contrast-enhanced MRI at least 1 year before extraction (n = 2) were analyzed and used as control samples...
September 2018: Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"